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Background: In the Valentines I trial, treatment of coronary in-stent restenosis was
effective and safe with the second-generation DIOR® paclitaxel drug-coated balloon
(DCB). We analyzed the effect of DCB treatment on patients with drug-eluting stent
(DES) restenosis.
Methods: Valentines I trial prospectively enrolled 250 patients with ISR. Of these, 74
patients (29.6%) had DES restenosis. Patients underwent balloon angioplasty followed by
DCB treatment. Clinical outcomes of patients with paclitaxel DES restenosis (34 patients
with 41 lesions) and -limus (sirolimus, everolimus and zotarolimus) DES restenosis (42
patients with 43 lesions) treated with DIOR® DCB were compared.
Results: Baseline characteristics were similar in both groups. There were more diffuse
pattern of restenosis in paclitaxel DES compared to -limus DES restenosis (50% vs.
26.8%, p0.032). Number of DCB used per patient (1.07 each group), mean DCB
diameter (2.95mm vs. 3.02mm), mean DCB length (26.7mm vs. 22.5mm) and bailout
stenting (2.6% vs. 4.7%) were similar in both groups (pNS). At mean follow-up of
231 43 days, major adverse cardiac events was 0% in the paclitaxel DES restenosis and
23.8% in the -limus DES restenosis (p0.002), the difference contributed mainly by less
target vessel revascularization (0 vs. 18.6%, p0.006) (Table).
Conclusion: In the Valentines I trial, the use of paclitaxel DCB was more effective in
patients with paclitaxel DES restenosis compared to -limus DES restenosis, achieving
better mid-term clinical outcomes. This suggests the efficacy of localized paclitaxel delivery
to overcome paclitaxel resistance but not -limus resistance due to different mechanisms of
DES failure.
Clinical outcomes at follow-up
Paclitaxel
DES
restenosis
(patients,
n34;
lesions,
n41)
Limus DES restenosis
(patients, n41;
lesions, n43) P value
Major adverse cardiac
events
0 10 (23.8%) 0.002
Death 0 1 (2.4%) 1.00
Myocardial infarction 0 1 (2.4%) 1.00
Vessel thrombosis 0 2 (4.8%) 0.50
Target lesion
revascularization
0 6 (14.0%) 0.027
Target vessel
revascularization
0 8 (18.6%) 0.006
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Objectives: This study aimed to determine how Excimer laser coronary atherectomy
(ELCA) performs in the drug-eluting stent (DES) era.
Background: For more than 20 years, ELCA has been used for coronary intervention.
With developments in the coronary intervention field, the role of ELCA is in question.
Methods: The study includes 119 patients with 124 lesions who underwent percutaneous
coronary intervention (PCI) with ELCA in our institution from January 2004 to May 2011.
Results (Table): The main indications for ELCA use were saphenous vein graft (SVG)
(45 lesions), acute myocardial infarction (AMI) (7 lesions), chronic total occlusion (CTO)
(32 lesions), in-stent restenosis (ISR) (15 lesions), and calcified de-novo lesions (25
lesions). High success rates were recorded for the SVG, AMI, CTO, ISR, and calcified
lesion indications (91.1%, 85.7%, 93.8%, 86.7%, and 80%; respectively). ELCA related
complications were reported in 10 patients (8%); four dissections, three no-reflow
phenomenon, two perforations, and one thrombus formation.
Conclusion: ELCA is an alternative solution with an acceptable performance in the
treatment of complex coronary lesions not ideally suitable for balloon angioplasty.
Saphenous
vein graft
lesion
(n45)
Acute
myocardial
infarction
(n7)
Chronic
total
occlusion
(n32)
In-stent
restenosis
(n15)
Calcified
lesions
(n25)
ELCA success® 41 (91.1%) 6 (85.7%) 30 (93.8%) 13 (86.7%) 20 (80%)
Angiographic
success¥
42 (93.3%) 7 (100%) 29 (90.6%) 14 (93.3%) 21 (84%)
Balloon non-crossable 2.0 (4.4%) 0 23 (71.9%) 2.0 (13.3%) 14 (56%)
Complications:
Dissection 0 0 3 (9.4%) 1 (6.7%) 0
Perforation 0 0 1 (3.1%) 0 1 (4.0%)
No-reﬂow 0 0 0 1 (6.7%) 2 (8.0%)
Thrombus formation 0 0 1 (3.1%) 0 0
®ELCA success was defined as the laser catheter crossing the entire length of the stenotic lesion
determined by angiographic evidence of the catheter tip in the artery distal to the stenosis. ¥Angio-
graphic successwas defined as50%residual stenosis after laser andadjunctive therapy
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Catheter-based Renal Denervation with the Symplicity™ System Provides Safe and
Durable Blood Pressure Reduction out to Three Years
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Background: The Symplicity™ renal denervation catheter uses low power radiofre-
quency energy to ablate the renal artery nerves and has been shown to lower blood pressure
(BP) in patients with treatment-resistant hypertension. Continued follow-up of patients
who have undergone renal denervation (RDN) is essential to establish the long-term
safety and effectiveness of this procedure.
Methods: The open-label Symplicity HTN-1 study enrolled 153 patients with severe
resistant hypertension (systolic BP 160 mm Hg in the presence of 3 antihypertensive
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